CutisPharma expands mouthwash compounding kit line
CutisPharma Inc. has extended its FIRST Magic Mouthwash line with four- and six-ounce BLM compounding kits.
CDR
Amneal rolls out generic Felbamate suspension
Amneal Pharmaceuticals has launched what it said is the first generic Felbamate oral suspension in 600 mg/5 ml strength. Amneal said Wednesday that the first-to-market product is an AB-rated, therapeutically equivalent alternative to Meda Pharmaceuticals’ Felbatol.
Walgreens stands firm in quarrel with PBM
With no resolution imminent in its stand-off with Express Scripts Inc., Walgreen Co. said it’s prepared to take a short-term hit rather than digest the long-term consequences of accepting the pharmacy benefit manager’s contract proposal.
MinuteClinic enters first clinical affiliation in Mass.
MinuteClinic has entered into a clinical collaboration with UMass Memorial Health Care, the largest health care system in central and western Massachusetts and the clinical partner of the University of Massachusetts Medical School.
PuraMed readies launch of migraine treatment
PuraMed BioScience Inc. is hatching plans for the national product launch of LipiGesic M, its clinically tested migraine headache treatment.
Medco shareholders OK Express Scripts merger
Medco Health Solutions Inc. shareholders have approved the company’s proposed merger with Express Scripts Inc.
Earnings at Walgreens tail off in first quarter
Net earnings slipped at Walgreen Co. in its fiscal 2012 first quarter as the drug chain cited its contract impasse with Express Scripts Inc., a slow cough/cold and flu season, and a tough year-over-year comparison as impacting results. Walgreens said Wednesday that for the first quarter ended Nov.
Prestige Brands to buy 17 OTC brands from GSK
Prestige Brands Holdings Inc. plans to acquire 17 over-the-counter pharmaceutical brands sold in North America from GlaxoSmithKline in $660 million cash deal.
Amgen, Watson team on oncology biosimilars
Amgen and Watson Pharmaceuticals Inc. plan to collaborate on the development and global commercialization of several oncology antibody biosimilar medicines.
CVS executives tout ‘unique suite of assets’
At its Analyst Day event in New York, CVS Caremark Corp. projected robust earnings and revenue growth for fiscal 2012 as executives cited health care trends that bode well for the company’s integrated business model, which combines a retail drug chain and pharmacy benefit management unit.
Bi-Lo set to merge with Winn-Dixie
Bi-Lo LLC and Winn-Dixie Stores Inc. have agreed to merge in a deal that stands to create a food and drug chain of nearly 690 stores in eight southeastern states. Under the merger agreement announced Monday, Bi-Lo plans to acquire all outstanding shares of Winn-Dixie stock for about $560 million.
Analyst Day Preview: CVS is well-positioned
Financial analysts are showing renewed faith in CVS Caremark Corp.’s integrated business model. Operating a retail drug store chain and a pharmacy benefit manager (PBM), the company is well-positioned to prosper amid recent shifts in the pharmacy sector, according to analysts.
Lawmakers to CMS: Don’t publish draft FUL lists
A group of 40 congressmen have called on the Centers for Medicare & Medicaid Services (CMS) to stop publishing draft lists of federal upper limits (FULs) used for reimbursing pharmacies under Medicaid.
American Diabetes Association names Walgreens as strategic partner
Walgreen Co. has become a national strategic partner of the American Diabetes Association (ADA) to collaborate with the organization on its Stop Diabetes effort.
CVS Caremark honored for logistics program
CVS Caremark Corp. has been awarded the 2011 Supply Chain Distinction Award North America in the Logistics Best Practice Category. CVS said Thursday that the awards, presented at the annual Supply Chain Logistics Summit in Dallas, held by media firm WTG Ltd.
NACDS clarifies ‘misleading’ statements by PBM execs
The National Association of Chain Drug Stores said the chief executive officers of Express Scripts and Medco Health Solutions made "misleading statements" in testimony at a Senate Judiciary subcommittee hearing on the two pharmacy benefit managers’ merger deal.